Report Thumbnail
Product Code LP09147134865ZK
Published Date 2026/5/22
English86 PagesGlobal

Global Tonic-Clonic Seizures Market Growth (Status and Outlook) 2026-2032Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP09147134865ZK
Published Date 2026/5/22
English 86 PagesGlobal

Global Tonic-Clonic Seizures Market Growth (Status and Outlook) 2026-2032Pharmaceutical_LifeSciense Market



Abstract


Summary

Epilepsy is a group of neurological disorders characterized by brief, involuntary episodes of vigorous shaking of a part or complete body. The patient may experience loss or disturbance of consciousness and movements along with sensory or psychiatric disturbances. Grand mal seizures or tonic–clonic seizures are a type of generalized seizures, which affect the entire brain and are the most common type of epileptic seizures. Grand mal seizures are caused by neurotransmitter imbalances, which can also be influenced by fatigue, lack of sleep, hypertension, stress, intense lighting, rapid motion, blood sugar level, anxiety, etc. The grand mal seizures consist of two phases, the tonic phase and the clonic phase. The tonic phase involves loss of consciousness and muscle twitching and the phase usually last only for a few seconds. The clonic phase consists of rapid muscle contraction and relaxation resulting in convulsions.
The global Tonic-Clonic Seizures market size is projected to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.
LPI (LP Information)' newest research report, the “Tonic-Clonic Seizures Industry Forecast” looks at past sales and reviews total world Tonic-Clonic Seizures sales in 2025, providing a comprehensive analysis by region and market sector of projected Tonic-Clonic Seizures sales for 2026 through 2032. With Tonic-Clonic Seizures sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tonic-Clonic Seizures industry.
This Insight Report provides a comprehensive analysis of the global Tonic-Clonic Seizures landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tonic-Clonic Seizures portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tonic-Clonic Seizures market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tonic-Clonic Seizures and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tonic-Clonic Seizures.
The Americas accounts for the significant market share owing to extensive use of medications and greater expenditure on the health care. Additionally, the fastest uptake of new technology and drugs in the US drives the global grand mal seizures market. The concentration of the major medical diagnostic device manufacturers in the developed regions is also adding fuel to the market. Europe is the second largest market due to a high disposable income and rising awareness about the grand mal seizures.
This report presents a comprehensive overview, market shares, and growth opportunities of Tonic-Clonic Seizures market by product type, application, key players and key regions and countries.
Segmentation by type
Barbiturates
Hydantoin
Phenyltriazine
Iminostilbenes
Benzodiazepines
Aliphatic Carboxylic Acid
Others
Segmentation by application
Hospitals
Clinics
Academic and Research Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Johnson & Johnson
UCB Celltech
Abbott Laboratories
GlaxoSmithKline
Novartis
Sanofi
Takeda
Teva Pharmaceutical

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Tonic-Clonic Seizures Market Size 2021-2032
      • 2.1.2 Tonic-Clonic Seizures Market Size CAGR by Region 2021 VS 2025 VS 2032
    • 2.2 Tonic-Clonic Seizures Segment by Type
      • 2.2.1 Barbiturates
      • 2.2.2 Hydantoin
      • 2.2.3 Phenyltriazine
      • 2.2.4 Iminostilbenes
      • 2.2.5 Benzodiazepines
      • 2.2.6 Aliphatic Carboxylic Acid
      • 2.2.7 Others
    • 2.3 Tonic-Clonic Seizures Market Size by Type
      • 2.3.1 Tonic-Clonic Seizures Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.3.2 Global Tonic-Clonic Seizures Market Size Market Share by Type (2021-2026)
    • 2.4 Tonic-Clonic Seizures Segment by Application
      • 2.4.1 Hospitals
      • 2.4.2 Clinics
      • 2.4.3 Academic and Research Centers
      • 2.4.4 Others
    • 2.5 Tonic-Clonic Seizures Market Size by Application
      • 2.5.1 Tonic-Clonic Seizures Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.5.2 Global Tonic-Clonic Seizures Market Size Market Share by Application (2021-2026)
  • 3 Tonic-Clonic Seizures Market Size by Player

    • 3.1 Tonic-Clonic Seizures Market Size Market Share by Players
      • 3.1.1 Global Tonic-Clonic Seizures Revenue by Players (2021-2026)
      • 3.1.2 Global Tonic-Clonic Seizures Revenue Market Share by Players (2021-2026)
    • 3.2 Global Tonic-Clonic Seizures Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion
  • 4 Tonic-Clonic Seizures by Regions

    • 4.1 Tonic-Clonic Seizures Market Size by Regions (2021-2026)
    • 4.2 Americas Tonic-Clonic Seizures Market Size Growth (2021-2026)
    • 4.3 APAC Tonic-Clonic Seizures Market Size Growth (2021-2026)
    • 4.4 Europe Tonic-Clonic Seizures Market Size Growth (2021-2026)
    • 4.5 Middle East & Africa Tonic-Clonic Seizures Market Size Growth (2021-2026)
  • 5 Americas

    • 5.1 Americas Tonic-Clonic Seizures Market Size by Country (2021-2026)
    • 5.2 Americas Tonic-Clonic Seizures Market Size by Type (2021-2026)
    • 5.3 Americas Tonic-Clonic Seizures Market Size by Application (2021-2026)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Tonic-Clonic Seizures Market Size by Region (2021-2026)
    • 6.2 APAC Tonic-Clonic Seizures Market Size by Type (2021-2026)
    • 6.3 APAC Tonic-Clonic Seizures Market Size by Application (2021-2026)
    • 6.4 China
    • 6.5 Japan
    • 6.6 Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
  • 7 Europe

    • 7.1 Europe Tonic-Clonic Seizures by Country (2021-2026)
    • 7.2 Europe Tonic-Clonic Seizures Market Size by Type (2021-2026)
    • 7.3 Europe Tonic-Clonic Seizures Market Size by Application (2021-2026)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Tonic-Clonic Seizures by Region (2021-2026)
    • 8.2 Middle East & Africa Tonic-Clonic Seizures Market Size by Type (2021-2026)
    • 8.3 Middle East & Africa Tonic-Clonic Seizures Market Size by Application (2021-2026)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Global Tonic-Clonic Seizures Market Forecast

    • 10.1 Global Tonic-Clonic Seizures Forecast by Regions (2027-2032)
      • 10.1.1 Global Tonic-Clonic Seizures Forecast by Regions (2027-2032)
      • 10.1.2 Americas Tonic-Clonic Seizures Forecast
      • 10.1.3 APAC Tonic-Clonic Seizures Forecast
      • 10.1.4 Europe Tonic-Clonic Seizures Forecast
      • 10.1.5 Middle East & Africa Tonic-Clonic Seizures Forecast
    • 10.2 Americas Tonic-Clonic Seizures Forecast by Country (2027-2032)
      • 10.2.1 United States Tonic-Clonic Seizures Market Forecast
      • 10.2.2 Canada Tonic-Clonic Seizures Market Forecast
      • 10.2.3 Mexico Tonic-Clonic Seizures Market Forecast
      • 10.2.4 Brazil Tonic-Clonic Seizures Market Forecast
    • 10.3 APAC Tonic-Clonic Seizures Forecast by Region (2027-2032)
      • 10.3.1 China Tonic-Clonic Seizures Market Forecast
      • 10.3.2 Japan Tonic-Clonic Seizures Market Forecast
      • 10.3.3 Korea Tonic-Clonic Seizures Market Forecast
      • 10.3.4 Southeast Asia Tonic-Clonic Seizures Market Forecast
      • 10.3.5 India Tonic-Clonic Seizures Market Forecast
      • 10.3.6 Australia Tonic-Clonic Seizures Market Forecast
    • 10.4 Europe Tonic-Clonic Seizures Forecast by Country (2027-2032)
      • 10.4.1 Germany Tonic-Clonic Seizures Market Forecast
      • 10.4.2 France Tonic-Clonic Seizures Market Forecast
      • 10.4.3 UK Tonic-Clonic Seizures Market Forecast
      • 10.4.4 Italy Tonic-Clonic Seizures Market Forecast
      • 10.4.5 Russia Tonic-Clonic Seizures Market Forecast
    • 10.5 Middle East & Africa Tonic-Clonic Seizures Forecast by Region (2027-2032)
      • 10.5.1 Egypt Tonic-Clonic Seizures Market Forecast
      • 10.5.2 South Africa Tonic-Clonic Seizures Market Forecast
      • 10.5.3 Israel Tonic-Clonic Seizures Market Forecast
      • 10.5.4 Turkey Tonic-Clonic Seizures Market Forecast
      • 10.5.5 GCC Countries Tonic-Clonic Seizures Market Forecast
    • 10.6 Global Tonic-Clonic Seizures Forecast by Type (2027-2032)
    • 10.7 Global Tonic-Clonic Seizures Forecast by Application (2027-2032)
  • 11 Key Players Analysis

    • 11.1 Pfizer
      • 11.1.1 Pfizer Company Information
      • 11.1.2 Pfizer Tonic-Clonic Seizures Product Offered
      • 11.1.3 Pfizer Tonic-Clonic Seizures Revenue, Gross Margin and Market Share (2021-2026)
      • 11.1.4 Pfizer Main Business Overview
      • 11.1.5 Pfizer Latest Developments
    • 11.2 Johnson & Johnson
      • 11.2.1 Johnson & Johnson Company Information
      • 11.2.2 Johnson & Johnson Tonic-Clonic Seizures Product Offered
      • 11.2.3 Johnson & Johnson Tonic-Clonic Seizures Revenue, Gross Margin and Market Share (2021-2026)
      • 11.2.4 Johnson & Johnson Main Business Overview
      • 11.2.5 Johnson & Johnson Latest Developments
    • 11.3 UCB Celltech
      • 11.3.1 UCB Celltech Company Information
      • 11.3.2 UCB Celltech Tonic-Clonic Seizures Product Offered
      • 11.3.3 UCB Celltech Tonic-Clonic Seizures Revenue, Gross Margin and Market Share (2021-2026)
      • 11.3.4 UCB Celltech Main Business Overview
      • 11.3.5 UCB Celltech Latest Developments
    • 11.4 Abbott Laboratories
      • 11.4.1 Abbott Laboratories Company Information
      • 11.4.2 Abbott Laboratories Tonic-Clonic Seizures Product Offered
      • 11.4.3 Abbott Laboratories Tonic-Clonic Seizures Revenue, Gross Margin and Market Share (2021-2026)
      • 11.4.4 Abbott Laboratories Main Business Overview
      • 11.4.5 Abbott Laboratories Latest Developments
    • 11.5 GlaxoSmithKline
      • 11.5.1 GlaxoSmithKline Company Information
      • 11.5.2 GlaxoSmithKline Tonic-Clonic Seizures Product Offered
      • 11.5.3 GlaxoSmithKline Tonic-Clonic Seizures Revenue, Gross Margin and Market Share (2021-2026)
      • 11.5.4 GlaxoSmithKline Main Business Overview
      • 11.5.5 GlaxoSmithKline Latest Developments
    • 11.6 Novartis
      • 11.6.1 Novartis Company Information
      • 11.6.2 Novartis Tonic-Clonic Seizures Product Offered
      • 11.6.3 Novartis Tonic-Clonic Seizures Revenue, Gross Margin and Market Share (2021-2026)
      • 11.6.4 Novartis Main Business Overview
      • 11.6.5 Novartis Latest Developments
    • 11.7 Sanofi
      • 11.7.1 Sanofi Company Information
      • 11.7.2 Sanofi Tonic-Clonic Seizures Product Offered
      • 11.7.3 Sanofi Tonic-Clonic Seizures Revenue, Gross Margin and Market Share (2021-2026)
      • 11.7.4 Sanofi Main Business Overview
      • 11.7.5 Sanofi Latest Developments
    • 11.8 Takeda
      • 11.8.1 Takeda Company Information
      • 11.8.2 Takeda Tonic-Clonic Seizures Product Offered
      • 11.8.3 Takeda Tonic-Clonic Seizures Revenue, Gross Margin and Market Share (2021-2026)
      • 11.8.4 Takeda Main Business Overview
      • 11.8.5 Takeda Latest Developments
    • 11.9 Teva Pharmaceutical
      • 11.9.1 Teva Pharmaceutical Company Information
      • 11.9.2 Teva Pharmaceutical Tonic-Clonic Seizures Product Offered
      • 11.9.3 Teva Pharmaceutical Tonic-Clonic Seizures Revenue, Gross Margin and Market Share (2021-2026)
      • 11.9.4 Teva Pharmaceutical Main Business Overview
      • 11.9.5 Teva Pharmaceutical Latest Developments
  • 12 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.